Ask Lazlo

life sciences… only

Tarceva Reaches Phase III Primary Endpoint

A press release yesterday from Genentech (DNA) reports that its drug Tarceva (erlotinib) reached its primary endpoint in a Phase III global clinical trial.  Tarceva is used to treat non-small cell lung cancer (NSCLC) and functions by interrupting the tyrosine kinase activity of epidermal growth factor receptor (EGFR).

The study demonstrated that treatment with Tarceva immediately following platinum-based chemotherapy increased the period of time without further disease progression in patients suffering from NSCLC.  

Tarceva was initially discovered by OSI Pharmaceuticals (OSI) and is the only EGFR inhibitor that that has been proven to increase survival rates in advanced NSCLC.  The drug is now marketed through a partnership between OSI and Genentech.

Advertisements

November 7, 2008 - Posted by | Biotech | , , , , , ,

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: